Literature DB >> 9811617

Filamentous nerve cell inclusions in neurodegenerative diseases.

M Goedert1, M G Spillantini, S W Davies.   

Abstract

Recent work has shown that abnormal filamentous inclusions within some nerve cells is a characteristic shared by Alzheimer's disease, some frontotemporal dementias, Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, as well as Huntington's disease and other trinucleotide repeat disorders. This suggests that in each of these disorders, the affected nerve cells degenerate as a result of these abnormal inclusions. Except for trinucleotide repeat disorders, the filaments involved have been shown to consist of either the microtubule-associated protein tau or alpha-synuclein. Over the past year, mutations in the genes for tau and alpha-synuclein have been identified as the genetic causes of some familial forms of frontotemporal dementia and Parkinson's disease, respectively. The discovery last year of neuronal intranuclear inclusions in Huntington's disease and other disorders with expanded glutamine repeats has suggested a unifying mechanism underlying the pathogenesis of this class of neurodegenerative diseases.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9811617     DOI: 10.1016/s0959-4388(98)80090-1

Source DB:  PubMed          Journal:  Curr Opin Neurobiol        ISSN: 0959-4388            Impact factor:   6.627


  44 in total

Review 1.  Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and alpha-synucleinopathies.

Authors:  M Goedert
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-06-29       Impact factor: 6.237

2.  Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation.

Authors:  L C Serpell; J Berriman; R Jakes; M Goedert; R A Crowther
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-25       Impact factor: 11.205

3.  Neuropathology in mice expressing human alpha-synuclein.

Authors:  H van der Putten; K H Wiederhold; A Probst; S Barbieri; C Mistl; S Danner; S Kauffmann; K Hofele; W P Spooren; M A Ruegg; S Lin; P Caroni; B Sommer; M Tolnay; G Bilbe
Journal:  J Neurosci       Date:  2000-08-15       Impact factor: 6.167

4.  The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity.

Authors:  N Ostrerova-Golts; L Petrucelli; J Hardy; J M Lee; M Farer; B Wolozin
Journal:  J Neurosci       Date:  2000-08-15       Impact factor: 6.167

5.  Understanding the kinetic roles of the inducer heparin and of rod-like protofibrils during amyloid fibril formation by Tau protein.

Authors:  Gayathri Ramachandran; Jayant B Udgaonkar
Journal:  J Biol Chem       Date:  2011-09-19       Impact factor: 5.157

6.  Mutations in tau gene exon 10 associated with FTDP-17 alter the activity of an exonic splicing enhancer to interact with Tra2 beta.

Authors:  Zhihong Jiang; Hao Tang; Necat Havlioglu; Xiaochun Zhang; Stefan Stamm; Riqiang Yan; Jane Y Wu
Journal:  J Biol Chem       Date:  2003-03-20       Impact factor: 5.157

7.  Pre-aggregated Aβ1-42 peptide increases tau aggregation and hyperphosphorylation after short-term application.

Authors:  Sabine Ott; Andreas Wolfram Henkel; Maria Kerstin Henkel; Zoran B Redzic; Johannes Kornhuber; Jens Wiltfang
Journal:  Mol Cell Biochem       Date:  2010-11-27       Impact factor: 3.396

8.  Structural basis for recognition of the RNA major groove in the tau exon 10 splicing regulatory element by aminoglycoside antibiotics.

Authors:  L Varani; M G Spillantini; M Goedert; G Varani
Journal:  Nucleic Acids Res       Date:  2000-02-01       Impact factor: 16.971

Review 9.  Cytoskeleton as a potential target in the neuropathology of maple syrup urine disease: insight from animal studies.

Authors:  R Pessoa-Pureur; M Wajner
Journal:  J Inherit Metab Dis       Date:  2007-06-14       Impact factor: 4.982

10.  p25alpha relocalizes in oligodendroglia from myelin to cytoplasmic inclusions in multiple system atrophy.

Authors:  Yun Ju C Song; Ditte M S Lundvig; Yue Huang; Wei Ping Gai; Peter C Blumbergs; Peter Højrup; Daniel Otzen; Glenda M Halliday; Poul H Jensen
Journal:  Am J Pathol       Date:  2007-09-06       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.